A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 9/26 (2006.01) A61K 9/58 (2006.01) A61K 31/403 (2006.01)
Patent
CA 2559685
The present invention relates to the pharmaceutical dosage forms which enable a controlled and/or a targeted delivery of an active substance to the selected regions of gastrointestinal tract of humans or animals. The pharmaceutical dosage forms preferably comprises the active substance N-(2~(2- phthalimidoethoxy)-acetyl)-L-alanyl-D-glutamic acid (designated as LK 423). Methods of treatment of chronic inflammatory diseases of gastrointestinal tract of humans and / or animals by using the pharmaceutical dosage forms of the invention are disclosed.
Cette invention se rapporte à des formes galéniques pharmaceutiques qui permettent une administration régulée et/ou ciblée d'une substance active dans les zones sélectionnées du tractus gastro-intestinal chez l'homme ou chez les animaux. Ces formes galéniques pharmaceutiques contiennent de préférence la substance active acide N-(2-(2-phtalimidoéthoxy)-acétyl)-L-alanyl-D-glutamique (appelée LK 423). Cette invention concerne également des procédés pour traiter les maladies inflammatoires chroniques du tractus gastro-intestinal chez l'homme et/ou chez les animaux en utilisant ces formes galéniques pharmaceutiques.
Bogataj Marija
Cerne Manica
Cof Greta
Dreu Rok
Kerc Janez
Goudreau Gage Dubuc
Lek Pharmaceuticals D.d.
LandOfFree
Gastroresistant pharmaceutical dosage form comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gastroresistant pharmaceutical dosage form comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gastroresistant pharmaceutical dosage form comprising... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1389009